International Flavors & Fragrances Inc (IFF)

Investment Committee Summary

Investment Thesis

At $85.81 (25 August 2026) the market values IFF on roughly 19 times forward earnings — a mid-cycle price that assumes volumes normalise, pricing holds against input costs, and the balance sheet deleverages without straining the dividend. The engine does not dispute the central case so much as the shape of the distribution around it. The twelve-month target of $76.50 and the probability-weighted $75.36 both sit under today's price, because gross-margin and multiple dispersion drive most of the variance and the structural and downturn paths together carry a large share of the tree's weight, pulling the median beneath the mean. The peer-multiple read implies a great deal more, but it reads as an optimism ceiling rather than a base case for a company that reported a loss at the net line in the most recent full year and whose depreciation now runs well above its capital expenditure — a legacy asset base being harvested rather than expanded. Triangulated fair value of $61.02 leaves the shares trading rich to the blend at -29%, which produces SELL, and the reported operating margin near 13% leaves little absorptive capacity. The single most damaging risk is a sustained raw-material squeeze that compresses margin while net debt of ~$5.2B limits the room to respond.

Narrative drafted 2026-08-16 by claude-opus-5 under supervision; reviewed by Marinus 2026-08-16.

The dashboard below is the whole argument on one page: spot ($85.81) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

The highest-probability bear is the industrial-recession complex, and the mechanism is credible rather than rhetorical. The company already reported a loss at the net line in the most recent full year, and depreciation running well above capital expenditure signals an asset base being harvested rather than renewed — exactly the position from which a downturn is hardest to absorb. In a demand slump, specialty and coatings volumes fall while customers destock, and pricing power erodes as raw-material spreads move against the producer. With net debt of ~$5.2B, leverage climbs mechanically as operating profit falls, forcing capital away from reinvestment and toward the balance sheet, and the dividend becomes a question rather than a given. Margin and the multiple then compress together, and the structural path — whose target sits below the fifty-two-week low — becomes the realistic reference point rather than a tail.

Key Debate

Gross Margin explains 57% of Monte Carlo outcome variance — the single variable that decides which side is right.

What the Market Is Pricing In

At the current price, the market pays 26.5× consensus forward EPS, vs the house DCF terminal 14.0×, and a peer median 24.1×. The house DCF sits 44% below spot, so the market is pricing in more than the house case — roughly 3.5pp of revenue CAGR.

Variant perception: the house view is below-consensus, and the thesis is primarily growth-driven.

Scenario Analysis

The scenario tree spans a structural 'Structural — Brand / Volume Erosion' downside ($33.70) to a 'Bull — Cycle + Re-Rate' bull case ($132); the probability-weighted blend (PWEV $75.36) is -12% versus spot.

Share-count charge: none applied. The probability-weighted value above is the gross per-share figure — no annual dilution is deducted — stock-based compensation runs at 0.8% of revenue; free cash flow net of SBC is $0.17B. SBC is therefore disclosed, not charged: read the per-share figures as before dilution.

Scenario rationale — the driver path behind every target:

• Structural — Brand / Volume Erosion (20%, $33.70). Structural impairment — raw-material squeeze / volume loss: earnings AND the multiple compress together. Target sits below the 52-week low by construction.
• Downturn — Construction / Industrial Slump (18%, $56.40). Cyclical downturn — specialty volumes + price/raw-material spread + specification lock-in weakens for 1–2 years before normalising.
• Base — Pricing-Led Compounding (33%, $79.50). Mid-cycle — normalised specialty volumes + price/raw-material spread + specification lock-in; disciplined capital allocation; steady returns.
• Growth — Share Gains + Mix (21%, $103). Upside — share gains + input deflation lifts earnings above mid-cycle; the multiple expands modestly.
• Bull — Cycle + Re-Rate (8%, $132). Upside tail — sustained tight conditions or a structural re-rate on share gains + input deflation.

Valuation Triangulation

Three weighted anchors — an intrinsic dcf, a scenario-weighted pwev and a monte carlo median (student-t + regime switching) — read them with their basis in mind. The Monte Carlo, the DCF terminal and any peer re-rate key off a market multiple, so they are not fully independent; only discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat three numbers as three independent votes.

The house blend DECLARES five anchor weights — DCF 35%, scenario PWEV 25%, Monte Carlo 15%, sum-of-parts 15%, peer re-rate 10%. For this name sum-of-parts, peer P/E re-rate are not computed, so 25% of the declared weight is redistributed across the anchors that exist — which is why the weights above differ from the declared ones. The fair value is unaffected by this disclosure; the blend has always worked this way.

Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.

Monte Carlo — the outcome distribution

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $67.54 and 32% of paths finish above spot. The variance decomposition shows the gross margin is the dominant swing factor (57% of variance). The fundamental driver, not the multiple, sets the spread — a cleaner setup.

DCF — the cash-flow anchor

Independent of the market multiple: a 5-year path, WACC 8.5%, 14.0x terminal FCF multiple → $47.98. This anchor is deliberately the heaviest (47%): it is the valuation least hostage to the current multiple regime.

Peer benchmarking — relative value

Against the peer cohort, re-rating to the peer-median EV/Revenue multiple implies $129; the peer-median forward P/E is 24.1x, but the engine carries no P/E-implied price for this name (no forward-EPS basis at the peer step). A premium is only justified by superior growth/margins; otherwise it is multiple risk. Excluded from the weighted blend — shown only as a market cross-check.

Across all anchors the spread is 108% of the median — wide (genuine disagreement — the blend carries low valuation confidence).

Sensitivity

DCF/share — WACC × terminal multiple

DCF/share — revenue CAGR Δ × op-margin Δ

Tornado — DCF/share swing by driver (widest first)

Company lever — SoP/share vs Specialty Chemicals & Formulated Materials multiple (AI re-rating) (base 17.0x)

Peer Quality & Weighting

Quality-weighted forward P/E: 20.9× (simple median 24.1×). Direct peers count 100%, segment 50%, broad 25%.

Historical-range cross-check: 52-week range $58.13–$88.07, centre $71.60 (-17% vs spot); spot sits at the 92nd percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.

Risk / Reward & Margin of Safety

That ratio compares triangulated upside against the probability-weighted bear target, not the extreme tail; with a leg missing it is withheld rather than computed from a magnitude. Bull case (Bull — Cycle + Re-Rate): $132.

Company Overview & Business Model

International Flavors & Fragrances Inc — BASIC MATERIALS · SPECIALTY CHEMICALS. International Flavors & Fragrances is an American corporation that produces flavors, fragrances, and cosmetic actives, which it markets globally. It is headquartered in New York City.

How it makes money.

Edge. Narrow moat — IFF's moat is customer formulation lock-in in flavours & fragrances (regulatory-registered, spec-locked into consumer products) plus scale in health/biosciences, but the post-merger integration overhang and leverage weaken it, so the moat is narrow. FALSIFIABLE: if volumes fail to recover and pricing cannot hold against input costs for two years while net debt stays above ~3x EBITDA, the ~17x forward multiple is not defensible and the terminal should sit at or below the specialty-chemicals ~14-16x range.

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Balance Sheet & Liquidity

Balance-sheet data as of 2025-12-31 (Alpha Vantage).

Capital Allocation

Free-Cash-Flow Quality

Accounting quality: SBC 1% of revenue.

Competitive Moat

Moat sources:

• Formulation/flavour lock-in: recipes designed into customer products, high requalification switching costs (FACT/INFERENCE)
• Scale and IP in fragrance and health & biosciences (enzymes, cultures) (FACT)
• Regulatory registration barriers on flavour/fragrance ingredients (FACT)
• Post-DuPont-N&B integration and ~$5.25bn net debt diluting the moat quality (INFERENCE)

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2026Q2): management +0.58 vs analyst floor +0.00 → delta +0.58 (n=24 mgmt / 14 Q&A; 84th pctile across the S&P book, z +1.1).

Flag: ELEVATED — management unusually upbeat vs the analyst floor relative to peers (disconfirmation watch).

News (last 365d, 1013 articles): avg ticker sentiment +0.16 (bullish 22% / bearish 5%)

Consensus & Market Expectations

_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.

Catalyst Calendar

• 2026-10-30 (~67d) — Portfolio divestiture / deleveraging milestone (net-debt reduction below ~3x EBITDA) (authored)
• 2026-12-05 (~103d) — Input-cost / pricing reset for the new contract year (authored)
• 2027-01-25 (~154d) — Volume-recovery inflection in Nourish / Scent as destocking ends (authored)

Forecast Track Record

• EPS surprise: beat 75% of the last 8 quarters; average surprise +0.5%.
• Prior-forecast backtest (12 snapshots, 2026-06-26→2026-08-20): directional hit-rate 33%; mean predicted -4.2% vs realised +7.4%. Disconfirming track record is reported, not suppressed.

Catalyst Timeline

6 catalysts in the next 90 days (of 16 tracked). Importance 1–3; confidence 0–1.

_Sources: extended.catalysts, data/catalysts/.json, data/catalysts/macro.json, AV DIVIDENDS, opex 3rd-Friday calc.

Regulatory & Legal Risk

Probabilities and sensitivities are analyst estimates, not market-implied.

Scenario Macro & Key Risks

Decision Rules (Machine-Checked)

Stance: Hold — 0 bullish / 0 bearish / 0 caution rules triggered of 5 evaluable (1 lacked data).

Machine-checked rules over disclosed inputs. The authored falsification triggers elsewhere in this report are analyst judgment and are NOT evaluated here. The stance is a portfolio-management signal and does not modify the published research rating.

Reasons the Thesis Could Fail (Falsifiable)

Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:

• Comparable (organic) volume growth < -0.02 (2 consecutive prints). (rationale withheld pending re-authoring — frozen figure or verdict)
• Adjusted operating (EBITDA) margin < 0.126 (2 consecutive prints). (rationale withheld pending re-authoring — frozen figure or verdict)
• Net debt / adjusted EBITDA > 4.0 (2 consecutive prints). (rationale withheld pending re-authoring — frozen figure or verdict)
• Full-year adjusted EPS guidance vs consensus < 4.2 (single event). (rationale withheld pending re-authoring — frozen figure or verdict)
• Capital expenditure run-rate > 0.78 (2 consecutive prints). (rationale withheld pending re-authoring — frozen figure or verdict)

Fact / Inference / Speculation

• FACT: Spot $85.81; 52-week range $58.13–$88.07; engine rating SELL; house target $76.50 (-11%). (source: Alpha Vantage 2026-08-24, 25 August 2026)
• INFERENCE: Triangulated FV $61.02 (-29% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the cash-flow anchor sits below the multiple-discipline core.
• SPECULATION: At current prices the embedded bet is that Gross Margin keeps surprising favourably — an operating call the next two prints will test.

Conviction Score

Research Conviction measures the strength and quality of the research setup — input coverage, financial quality, valuation support, process agreement. It is NOT the probability that the recommendation succeeds; the forecast track record section is the evidence on that.

47.4/100 (confidence band 34.1–60.8), 11th percentile of 858 covered names (as of 2026-08-24). Weighted composite under config ros-1.19.0 — every component and its inputs below.

Missing inputs (macro tailwinds) are excluded and the remaining weights renormalised; the confidence band widens accordingly.

Score history: 48.2 → 48.2 → 52.6 → 48.4 → 48.4 → 47.9 → 47.7 → 47.7.

Probability-Weighted Return Profile

Horizon: 1 year — at this horizon CAGR equals total return by definition. Expected values are the probability-weighted sums over the full scenario set below.

The gross expected return is the probability-weighted scenario return (it reconciles to the gross PWEV); the diluted figure applies the SBC share-count charge and matches the published PWEV-based target.

Expected Alpha

Expected return minus the return this name is REQUIRED to deliver for its risk (1-year horizon). Constants are pre-registered (preregistered-static (amendment #2, 2026-07-29); not fitted to MCH outcomes).

A negative expected alpha does not change the rating — it says the expected return does not clear the risk-adjusted hurdle at today's price. Rating mechanics are unchanged by this section.

Probability Cross-Checks

Not authoritative. The scenario probabilities in this report are AUTHORED — a judgement about how the world might go, not a measurement. Nothing below modifies them, the target, the rating or any position size. These checks ask only whether anything outside our own model agrees with us; where it does not, that is information for the reader, not a correction we have quietly applied.

Authored set: 5 scenarios, probabilities summing to 1.0, mean target $75.36.

Factor Exposures

Cross-sectional percentiles over 858 covered names (style scores sector-demeaned; thematic = return-beta to the theme's proxy ETF). 50 = estate median.

Market interaction: correlation vs SPY +0.35, vs QQQ +0.27 (trailing ~1y daily returns).

Options Intelligence

Preferred structure: Put Debit Spread. The selector reads the equity view (direction) and the volatility surface — nothing here re-prices the chain.

• bearish with cheap options — buy defined-risk downside
• Direction bearish from the overlay conviction/rating (read-only input).
• IV/RV at the 17th percentile of the cross-section → low vol bucket. This is the measure that selects the structure above: it ranks how rich this name's implied vol is against its own realised vol, relative to other names.
• Reported alongside and not used to select: this name's own ATM IV sits at the 25th percentile of its own month-end history (decile 3).
• IV term structure is in contango (longer-dated richer, slope +9.8pp) — favour longer-dated ownership (LEAPS) or calendars that are long the cheaper front.

IV term structure (contango, slope +9.8pp): 25-DTE 25% · 88-DTE 29% · 389-DTE 35%

Economics copied verbatim from the options overlay (priced from the listed chain (EOD marks)); the selector does not re-price.

Alternatives: Protective Put. IV rank shown via the name's own monthly IV history (advisory); structure selected on the cross-sectional IV/RV percentile. Model output for research and education only — not individualised investment advice. Position-sizing and stance figures are mechanical outputs of the disclosed rules and inputs; they do not consider any person's objectives, financial situation, or tax status.

Position Sizing Framework

research rating is SELL-tier — the model carries no long position.

Model output for research and education only — not individualised investment advice. Position-sizing and stance figures are mechanical outputs of the disclosed rules and inputs; they do not consider any person's objectives, financial situation, or tax status.

Options Overlay

A defined-risk way to express the SELL equity view. Chain as of 2026-08-24 — end-of-day marks — indicative, not executable quotes.

Market signals — ATM IV 24.9% (subdued regime) · expected move ±5.2% (2026-09-18) · put/call OI 0.90 · ATM Δ 0.59 / Θ -0.05 / ν 0.09. Direction: SHORT/HEDGE (implied return -28.9% to triangulated fair value $61.02).

Bear Put Spread (Bearish) — Long 85 P / Short 60 P · 2027-02-19 · net debit $4.67 · max profit $20.32 · breakeven $80.33 · RoR 435.0% · max loss $4.67 · priced from the listed chain (EOD marks)

Defined-risk downside expression: the debit caps the loss, with the position gaining as the stock falls toward the lower strike — a way to act on a bearish view without shorting stock. Subdued implied volatility currently lowers the premium paid. Illustrative — no outcome is implied or guaranteed.

Protective Put (if held) (Hedge) — Long 85 P · 2027-02-19 · premium $6.35 · floor -1.0% · max loss $6.35 · priced from the listed chain (EOD marks)

Insurance for an existing holding — a known premium buys a floor while leaving the upside intact. A way to hold through a binary event or volatility with defined downside.

Protective Collar (if held) (Hedge) — Long 77.5 P / Short 95 C · 2027-02-19 · net $0.67 · floor -10.0% · cap +11.0% · priced from the listed chain (EOD marks)

For a holder who wants to stay invested but cap risk: the sold call funds most of the protective put, fencing the position into a band — a way to ride out a de-rating without selling.

Indicative options structures — a defined-risk expression of the equity view, model-and-market illustrated from the last-close chain. NOT personalised advice or an executable quote; premiums, IV and greeks move intraday. Options carry the risk of total loss of premium. Not a registered financial adviser.

Rating Bridge

Rating = SELL because:

• Probability-weighted scenario value implies -12% vs spot
• Monte Carlo median implies -21% vs spot
• DCF fair value implies -44% vs spot — but this is terminal-value sensitive (exit-multiple $47.98 vs Gordon $58.82, 23% apart), so it carries less weight
• Bear case (Structural — Brand / Volume Erosion) downside is -61% vs spot
• Net: the valuation anchor itself sits 28.9% below spot, so there is no reward leg to weigh against the bear case and the reward-to-risk ratio is withheld rather than computed off a negative upside. The rating warrants a Sell.

Model Appendix

DCF — line items

FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 4% of revenue, weighted from the segments) — not a single conversion fudge.

WACC 8.5% · Σ PV(FCF) $5B + PV(terminal) $13B = EV $18B; − net debt $5.2B → equity $12B ÷ diluted shares $0.26B = $47.98/share (exit-multiple terminal).

• Gordon terminal at 2.5% → $58.82/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
• Incremental ROIC on the forecast capex ≈ 8% vs WACC 8.5% → below WACC — the incremental build is value-dilutive.

Peer set

Implied prices at the peer medians: EV/Rev → $129 (no P/E-implied price — no forward-EPS basis at the peer step).

Weighted fair-value math

Assumption Register

Sensitivity-ranked drivers (widest fair-value swing first): Op margin ±3pp (31.0); Revenue CAGR ±3pp (18.0); Terminal × ±15% (15.0); Capex intensity ±15% (11.0); WACC ±1pp (6.0).

Inputs, Sources & Confidence

Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)

Research Provenance

Load-Bearing Assumptions

DCF: WACC 8.5%, terminal multiple 14×, FY+5 revenue $13B. Triangulation leans 47% on DCF, 33% on PWEV, 20% on the Monte Carlo median.